What happened
Hanmi Pharm filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$322M (+29.3% year on year), operating profit of US$90.2M (+116.9% year on year) and net income of US$57.9M (+95.5% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$322M |
|---|---|
| Revenue vs a year earlier | +29.3% |
| Operating profit | US$90.2M |
| Net income | US$57.9M |
| Period | Q2 2026 (consolidated) |
| Filed | 2026-07-28, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260728800599 → open original filing |
Source: DART. Information only, not investment advice.